VISIPAQUE iodixanol 5.5g/10mL (550mg/mL) injection ampoule Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 5.5g/10ml (550mg/ml) injection ampoule

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; hydrochloric acid; sodium chloride; trometamol; sodium hydroxide; calcium chloride dihydrate - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 110g/200mL (550mg/mL) injection bag Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 110g/200ml (550mg/ml) injection bag

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium calcium edetate; sodium chloride; water for injections; sodium hydroxide; calcium chloride dihydrate; trometamol - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 82.5g/150mL (550mg/mL) injection bag Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 82.5g/150ml (550mg/ml) injection bag

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium chloride; calcium chloride dihydrate; trometamol; water for injections; sodium calcium edetate - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 55g/100mL (550mg/mL) injection bag Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 55g/100ml (550mg/ml) injection bag

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: water for injections; calcium chloride dihydrate; sodium calcium edetate; trometamol; sodium hydroxide; hydrochloric acid; sodium chloride - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 110g/200mL (550g/mL) injection bottle Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 110g/200ml (550g/ml) injection bottle

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 82.5g/150mL (550mg/mL) injection bottle Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 82.5g/150ml (550mg/ml) injection bottle

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 55g/100mL (550g/mL) injection bottle Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 55g/100ml (550g/ml) injection bottle

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 27.5g/50mL (550mg/mL) injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 27.5g/50ml (550mg/ml) injection vial

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

MUPIROCIN ointment USA - engelsk - NLM (National Library of Medicine)

mupirocin ointment

keltman pharmaceuticals inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment, 2% is indicated for the topical treatment of impetigo due to: staphylococcus aureus and streptococcus pyogenes . this drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

IPRATROPIUM BROMIDE- ipratropium bromide solution USA - engelsk - NLM (National Library of Medicine)

ipratropium bromide- ipratropium bromide solution

nucare pharmaceuticals,inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide   inhalation solution 0.02%   read complete instructions carefully before using. - twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir (figure 1). - connect the nebulizer reservoir to the mouthpiece or face mask (figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) or put on the face mask and turn on the compressor. if a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of v